Korro Bio(US:KRRO) ZACKS·2026-03-13 00:20Core Insights - Korro Bio, Inc. reported a quarterly loss of $5.32 per share, significantly worse than the Zacks Consensus Estimate of a loss of $1.93, marking an earnings surprise of -175.08% [1] - The company's revenues for the quarter were $1.29 million, missing the Zacks Consensus Estimate by 13.87%, and down from $2.27 million a year ago [2] - Korro Bio's stock has increased by approximately 46.8% since the beginning of the year, contrasting with a 1% decline in the S&P 500 [3] Financial Performance - Over the last four quarters, Korro Bio has surpassed consensus EPS estimates two times, but has not beaten revenue estimates during the same period [2] - The current consensus EPS estimate for the upcoming quarter is -$1.86 on revenues of $1.5 million, and for the current fiscal year, it is -$7.01 on revenues of $6 million [7] Market Outlook - The company's earnings outlook is crucial for assessing future stock performance, with recent estimate revisions trending unfavorably, resulting in a Zacks Rank 4 (Sell) [6] - The Medical - Drugs industry, to which Korro Bio belongs, is currently in the top 35% of Zacks industries, indicating a favorable industry outlook [8]